Renaissance Technologies LLC recently announced the acquisition of new stake in Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN). The institutional investor has increased its shareholding in the Healthcare company by 87.40% to 3.15 million shares with purchase of 1.47 million shares. This fresh investment now brings its stake to 5.31% valued currently at $3.62 million. In addition, BlackRock Fund Advisors raised its holdings by 9692.0 to 0.83 million shares. And Geode Capital Management LLC has lifted its position by 95.07% or 0.17 million shares – to 0.34 million shares.

With over 2.65 million Diffusion Pharmaceuticals Inc. (DFFN) shares trading Tuesday and a closing price of $0.91 on the day, the dollar volume was approximately $2.41 million. The shares have shown a negative weekly performance of -13.33% and its price on 09/01/20 lost nearly -7.10%. Currently, there are 64.00M common shares owned by the public and among those 63.83M shares have been available to trade.

An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for DFFN have a consensus price objective of $3.50. The analysts have set the share’s price value over the next 12 months at a high of $3.50 and a low of $3.50 should the stock experience a downside. But an upside of 74.0% will see the stock hit the forecast high price target while mean target price for the stock is $3.50.

Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.

The top 3 mutual fund holders in Diffusion Pharmaceuticals Inc. are Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Fidelity Comwlth. Tr. – Nasdaq Co. Vanguard Extended Market Index Fu owns 0.31 million shares of the company’s stock, all valued at over $0.36 million. The company bought an additional 30972.0 shares recently to bring their total holdings to about 0.53% of the shares outstanding. Fidelity Comwlth. Tr. – Nasdaq Co sold 43225.0 shares to bring its total holdings to over 0.11 million shares at a value of $0.12 million. Fidelity Comwlth. Tr. – Nasdaq Co now owns shares totaling to 0.18% of the shares outstanding.

Shares of Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) opened at $0.9528, down -$0.03 from a prior closing price of $0.98. However, the script later closed the day at $0.91, down -7.10%. The company’s stock has a 5-day price change of -13.33% and -21.55% over the past three months. DFFN shares are trading 97.53% year to date (YTD), with the 12-month market performance down to -53.42% lower. It has a 12-month low price of $0.21 and touched a high of $2.27 over the same period. Currently, 2.65 million shares have been traded, compared to an average intraday trading volume of 2.94 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -15.40%, -15.32%, and 34.07% respectively.

Institutional ownership of Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) shares accounts for 11.00% of the company’s 64.00M shares outstanding. Mutual fund holders own 1.08%, while other institutional holders and individual stakeholders account for 7.82% and 0.12% respectively.

It has a market capitalization of $56.71M and a beta (3y monthly) value of 1.26. The earnings-per-share (ttm) stands at -$1.02. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.71% over the week and 6.80% over the month.

Analysts forecast that Diffusion Pharmaceuticals Inc. (DFFN) will achieve an EPS of -$0.06 for the current quarter, -$0.06 for the next quarter and -$0.24 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.07 while analysts give the company a high EPS estimate of -$0.06. Comparatively, EPS for the current quarter was -$0.6 a year ago. Earnings per share for the fiscal year are expected to increase by 78.90%, and 14.30% over the next financial year.

Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”

Looking at the support for the DFFN, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on March 21, 2018, with the firm’s price target at $1.25.